Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Nephrology
•
Onconephrology
•
Tumor Lysis Syndrome
•
Hospital Medicine
Do you recommend testing for G6PD deficiency in those with whom rasburicase for tumor lysis syndrome is indicated?
Answer from: at Academic Institution
G6PD deficiency is a contraindication to the use of rasburicase and should be tested for prior to the use of this drug.
Sign In
or
Register
to read more
Answer from: at Community Practice
You're supposed to test, but most do not. It's X-linked, so males are more susceptible. Certain populations are too: sub-Saharan Africa, the Mediterranean, and Southeast Asia.
Sign In
or
Register
to read more
17203
17204
Related Questions
What are some important considerations for use of ACE inhibition in scleroderma renal crisis patients who require dialysis?
Would you recommend administering IV amino acids prior to cardiac surgery with cardiopulmonary bypass, given recent trial findings of improved AKI rates but no significant difference in kidney-replacement therapy with IV amino acids?
Would you continue to monitor urinary protein levels and dose adjust axitinib in a patient with metastatic malignancy who is now dialysis dependent but has residual renal function?
Do you recommend holding ACE inhibitors, ARBs, and SGLT2 inhibitors for patients with chronic kidney disease and malignancy who are about to start high-dose intravenous methotrexate?
Would you recommend desmopressin for a patient with ESKD receiving thrice weekly hemodialysis who is hospitalized for a persistent gastrointestinal bleed not amenable to usual interventional treatment strategies?
Do you routinely continue dual antibiotic coverage or de-escalate to monotherapy based on peritoneal fluid culture sensitivities in patients with relapsing pseudomonas aeruginosa peritoneal dialysis peritonitis after peritoneal catheter removal?
Would you recommend starting tolvaptan at 7.5 mg per day, which is half the typical starting dose, to reduce the risk of overcorrection in an inpatient with SIADH and a serum sodium level of 122 mEq/L?
How do you reconcile the risk of contrast-induced nephropathy (CIN) with the diagnostic benefit of contrasted CT in patients with AKI/CKD?
How often do you check fibrinogen levels and when do you administer FFP for patients with AKI requiring plasma exchange?
How would you approach management and monitoring of AL amyloidosis with isolated renal involvement?